WINNIPEG, Manitoba, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech” or “Kane”) announces that it has filed a patent on its revyve™ Antimicrobial Wound Gel Spray, a follow-on product to its FDA 510(k) cleared revyve™ Antimicrobial Wound Gel, and will be introducing it today at the Boswick Burn and Wound Care Symposium.
“Kane has taken their revyve™ Antimicrobial Wound Gel and loaded it into this new, patent-pending delivery system creating a highly differentiated product ideal for burns and other sensitive wounds”, stated Dr. Gregory Schultz, Chief Scientific Officer of Kane Biotech. “The spray application makes it very easy to apply to the wound, and its thermo-reversible properties allow the gel to adhere to the skin on contact and makes it very easy to rinse off with cool water. This eliminates any need for direct physical contact with the burn wound and reduces the risk of infection as well as pain for the patient. I expect the product to be well received at this conference.”
Kane is in the final stages of development of this product which is still pending FDA clearance. “We believe this new application system with its optimum spray pattern, will have such a significant impact on treating sensitive wounds, in particular burns, that Kane has filed a patent”, said Marc Edwards, Chief Executive Officer of Kane Biotech. “We are very excited about this product and are working towards a commercial launch by the end of 2024.”
The following link includes a demonstration of the spray gel being applied and easily rinsed off with water: https://kanebiotech.com/#videos
The Boswick Burn and Wound Care Symposium is an international conference that covers the latest advancements in wound healing, burn care, and infection control.
About Kane Biotech
Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Company has a portfolio of biotechnologies, intellectual property (80 patents and patents pending, trade secrets and trademarks) and products developed by the Company's own biofilm research expertise and acquired from leading research institutions. StrixNB™, DispersinB®, Aledex™, bluestem™, bluestem®, silkstem™, goldstem™, coactiv+™, coactiv+®, DermaKB™, DermaKB Biofilm™ and revyveTM are trademarks of Kane Biotech Inc. The Company is listed on the TSX Venture Exchange under the symbol "KNE" and on the OTCQB Venture Market under the symbol “KNBIF”.
| For more information: | ||
| Marc Edwards | Ray Dupuis | Nicole Sendey |
| Chief Executive Officer | Chief Financial Officer | Investor Relations/PR |
| Kane Biotech Inc. | Kane Biotech Inc. | Kane Biotech Inc. |
| medwards@kanebiotech.com | rdupuis@kanebiotech.com | nsendey@kanebiotech.com |
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Caution Regarding Forward-Looking Information
This press release contains certain statements regarding Kane Biotech Inc. that constitute forward-looking information under applicable securities law. These statements reflect management’s current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, risks relating to the Company’s: (a) financial condition, including lack of significant revenues to date and reliance on equity and other financing; (b) business, including its early stage of development, government regulation, market acceptance for its products, rapid technological change and dependence on key personnel; (c) intellectual property including the ability of the Company to protect its intellectual property and dependence on its strategic partners; and (d) capital structure, including its lack of dividends on its common shares, volatility of the market price of its common shares and public company costs. Further information about these and other risks and uncertainties can be found in the disclosure documents filed by the Company with applicable securities regulatory authorities, available at www.sedarplus.ca. The Company cautions that the foregoing list of factors that may affect future results is not exhaustive.
